High Proportion of PNH Type II Neutrophils Is Associated With Thrombosis in Patients Displaying a PNH Clone ≥ 1%
Year: 2026
Type: article
Study design: Observational Study
Abstract: The clinical significance of PNH Type II white blood cells (WBCs) remains unclear. We assessed the relative percentage (rel%) of Type II neutrophils in 355 patients with a PNH clone ≥ 1% on neutrophils enrolled by 33 flow cytometry laboratories in the 5-year French nation-wide multicenter prospective observational study. We first analyzed 127 of 133 patients with a major PNH clone (≥ 50%) and evaluable Type II neutrophil rel%. Using hemolysis data available for 107 patients, a threshold of 3% Type II neutrophils rel% distinguished two groups: 22 "high Type II" and 105 "low Type II" patients. Hemolysis was less frequent in the "high Type II" group. Thrombosis was more frequent at diagnosis and during cumulative long-term follow-up in this group. High neutrophil rel% ≥ 3% was independently associated with thrombotic events. Among 222 patients with smaller PNH clones (1%-50%), 207 displayed evaluable Type II neutrophil rel%, of which 87 were classified as "high Type II" and 120 as "low Type II". Although no thrombosis was present at diagnosis, two thrombotic events occurred during follow-up in the "high Type II" group, whereas none were observed in the "low Type II" group. Long-term follow-up showed no major changes in Type II neutrophil rel%, irrespective of variations in total clone size. These findings suggest that, regardless of the total PNH clone size, PNH Type II neutrophil rel% is a stable parameter and may represent a reliable predictor of thrombosis, potentially supporting earlier consideration of anticomplement therapy initiation.
Source: American Journal of Hematology
DOI: 10.1002/ajh.70431
Authors: Orianne Wagner‐Ballon, Anne‐Catherine Lhoumeau, Anna Raimbault, Camille Debord, Jean‐Philippe Vial, Valérie Soenen, Mélanie Pannetier, Edouard Bonneville, Elsa Bera, Caroline Bret, Nicolas Chapuis, Véronique Latger‐Cannard, Caroline Mayeur‐Rousse, Véronique Harrivel, François Vergez, Marie Loosveld, Juliette Vo Xuan, Stéphanie Mathis, Gérard Socié, Flore Sicre de Fontbrune, Régis Peffault de Latour, Bernard Drenou, Agathe Debliquis, Magali Le Garff‐Tavernier, the French PNH working group CytHem‐HPN
Institutions: Inserm, Université Paris-Est Créteil, Centre Hospitalier Universitaire Henri-Mondor, Hôpitaux Universitaires Henri-Mondor, Institut Mondor de Recherche Biomédicale, Institut Paoli-Calmettes, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis, Centre Hospitalier Universitaire de Nantes, Centre Hospitalier Universitaire de Bordeaux, Centre Hospitalier Universitaire de Lille, Centre Hospitalier Universitaire de Rennes, Centre Hospitalier Universitaire de Grenoble, Centre Hospitalier Universitaire de Rouen, Centre Hospitalier Universitaire de Montpellier, Hôpital Cochin, Laboratoire d'hématologie, Centre Hospitalier Régional et Universitaire de Nancy, Hôpitaux Universitaires de Strasbourg, Centre Hospitalier Universitaire Amiens-Picardie, Centre Hospitalier Universitaire de Toulouse, Hôpital de la Timone, Groupe Hospitalier de la Région de Mulhouse et Sud Alsace, Université Paris Cité, Sorbonne Université, Centre de Recherche des Cordeliers, Pitié-Salpêtrière Hospital
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $5,450
Funder: Alexion Pharmaceuticals
OpenAlex ID: W7167347236
